Pro-Dex (PDEX) 10-Q 30 Jan 25 2025 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2024	Jan. 28, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--06-30
Entity File Number	0-14942
Entity Registrant Name	PRO-DEX, INC.
Entity Central Index Key	0000788920
Entity Tax Identification Number	84-1261240
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	2361 McGaw Avenue
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92614
City Area Code	949
Local Phone Number	769-3200
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	PDEX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,261,043

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Current assets:
Cash and cash equivalents	$ 66	$ 2,631
Investments	4,671	4,217
Accounts receivable, net of allowance for expected credit losses of $27 and $0 at December 31, 2024 and at June 30, 2024, respectively	18,467	13,887
Deferred costs	152	262
Inventory	19,611	15,269
Prepaid expenses and other current assets	1,333	345
Total current assets	44,300	36,611
Land and building, net	6,108	6,155
Equipment and leasehold improvements, net	5,443	5,024
Right-of-use asset, net	1,265	1,473
Intangibles, net	40	54
Deferred income taxes, net	1,555	1,555
Investments	1,619	1,563
Other assets	44	42
Total assets	60,374	52,477
Current liabilities:
Accounts payable	5,689	4,513
Accrued liabilities	5,234	3,359
Income taxes payable	303	632
Deferred revenue		14
Notes payable	5,913	4,374
Total current liabilities	17,139	12,892
Lease liability, net of current portion	939	1,182
Notes payable, net of current portion	10,474	7,536
Total non-current liabilities	11,413	8,718
Total liabilities	28,552	21,610
Shareholders’ equity:
Common stock; no par value; 50,000,000 shares authorized; 3,260,390 and 3,363,412 shares issued and outstanding at December 31, 2024 and June 30, 2024, respectively	366	3,917
Retained earnings	31,456	26,950
Total shareholders’ equity	31,822	30,867
Total liabilities and shareholders’ equity	$ 60,374	$ 52,477

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Statement of Financial Position [Abstract]
Net of allowance for expected credit losses	$ 27	$ 0
Common stock, no par value	$ 0	$ 0
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	3,260,390	3,363,412
Common stock, shares outstanding	3,260,390	3,363,412

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Net sales	$ 16,793	$ 12,588	$ 31,686	$ 24,526
Cost of sales	11,721	9,786	21,464	18,066
Gross profit	5,072	2,802	10,222	6,460
Operating expenses:
Selling expenses	49	37	98	63
General and administrative expenses	1,389	1,200	2,635	2,195
Research and development costs	942	788	1,784	1,593
Total operating expenses	2,380	2,025	4,517	3,851
Operating income	2,692	777	5,705	2,609
Interest expense	(204)	(139)	(357)	(271)
Unrealized gain (loss) on marketable equity investments	77	(40)	510	(2,593)
Interest and other income	21	22	46	46
Income (loss) before income taxes	2,586	620	5,904	(209)
Income tax benefit (expense)	(546)	(120)	(1,398)	94
Net income (loss)	$ 2,040	$ 500	$ 4,506	$ (115)
Basic net income (loss) per share
Net income (loss) per share	$ 0.63	$ 0.14	$ 1.36	$ (0.03)
Diluted net income (loss) per share:
Net income (loss) per share	$ 0.61	$ 0.14	$ 1.33	$ (0.03)
Weighted-average common shares outstanding:
Basic	3,261,145	3,546,901	3,314,207	3,546,819
Diluted	3,337,337	3,611,701	3,378,862	3,546,819
Common shares outstanding	3,260,390	3,541,045	3,260,390	3,541,045

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Retained Earnings [Member]	Total
Balance, beginning of period at Jun. 30, 2023	$ 6,767	$ 24,823	$ 31,590
Share-based compensation expense	386
Share repurchases	(107)
Shares withheld from common stock issued to pay employee payroll taxes
ESPP shares issued	32
Net income		(115)	(115)
Balance, end of period at Dec. 31, 2023	7,078	24,708	31,786
Balance, beginning of period at Sep. 30, 2023	6,987	24,208	31,195
Share-based compensation expense	198
Share repurchases	(107)
Shares withheld from common stock issued to pay employee payroll taxes
ESPP shares issued
Net income		500	500
Balance, end of period at Dec. 31, 2023	7,078	24,708	31,786
Balance, beginning of period at Jun. 30, 2024	3,917	26,950	30,867
Share-based compensation expense	243
Share repurchases	(3,504)
Shares withheld from common stock issued to pay employee payroll taxes	(305)
ESPP shares issued	15
Net income		4,506	4,506
Balance, end of period at Dec. 31, 2024	366	31,456	31,822
Balance, beginning of period at Sep. 30, 2024	1,461	29,416	30,877
Share-based compensation expense	130
Share repurchases	(1,192)
Shares withheld from common stock issued to pay employee payroll taxes	(33)
ESPP shares issued
Net income		2,040	2,040
Balance, end of period at Dec. 31, 2024	$ 366	$ 31,456	$ 31,822

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 4,506	$ (115)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	615	568
Share-based compensation	243	386
Unrealized (gain) loss on marketable equity investments	(510)	2,593
Non-cash lease recovery	(14)	(7)
Amortization of loan fees, net	13
Credit loss expense	27
Changes in operating assets and liabilities:
Accounts receivable	(4,606)	(3,217)
Deferred costs	109	82
Inventory	(4,342)	1,141
Prepaid expenses and other assets	(991)	(605)
Accounts payable and accrued expenses	3,030	340
Deferred revenue	(14)
Income taxes payable	(329)	(64)
Net cash provided by (used in) operating activities	(2,263)	1,102
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of investments		(1,250)
Purchases of equipment and improvements	(973)	(759)
Net cash used in investing activities	(973)	(2,009)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchases of common stock	(3,504)	(107)
Proceeds from ESPP contributions	15	32
Payment of employee payroll taxes on net issuance of common stock	(305)
Proceeds from Minnesota Bank & Trust revolving loan	8,490	2,000
Principal payments on notes payable and revolving loan	(4,025)	(2,665)
Net cash provided by (used in) financing activities	671	(740)
Net decrease in cash and cash equivalents	(2,565)	(1,647)
Cash and cash equivalents, beginning of period	2,631	2,936
Cash and cash equivalents, end of period	66	1,289
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	338	272
Cash paid during the period for income taxes by jurisdiction:
Federal income tax payments	1,570	565
California income tax payments	1,100	74
Massachusetts income tax payments		21
Total income tax payments	2,670	660
Non-cash investing and financing activity:
Cashless stock option exercise	$ 117

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ 2,040	$ 500	$ 4,506	$ (115)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Dec. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
BASIS OF PRESENTATION	NOTE 1. BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements of Pro-Dex, Inc. (“we,” “us,” “our,” “Pro-Dex,” or the “Company”) have been prepared in accordance with principles generally in United States (“U.S. GAAP”) interim financial information and the instructions to Form 10-Q and applicable provisions of Regulation S-K. Accordingly, they not include all of the information and footnotes required U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the financial statements presented in our Annual Report Form 10-K for the fiscal year ended June 30, 2024. In the opinion of management, all adjustments considered necessary for fair presentation have been included. The results of operations for such interim periods are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended June 30, 2024. Recently Issued and Not Yet Adopted Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes: Improvements to Income Tax Disclosures (Topic 740) In November 2023, the FASB issued ASU 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures (Topic280),

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	6 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 2. DESCRIPTION OF BUSINESS We specialize in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adaptive torque-limiting software and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. We also manufacture and sell rotary air motors to a wide range of industries. In August 2020, we formed a wholly owned subsidiary, PDEX Franklin, LLC (“PDEX Franklin”), to hold title for an approximate 25,000 square foot industrial building in Tustin, California (the “Franklin Property”) that we acquired in November 2020, to allow for the continued growth of our business. The condensed consolidated financial statements include the accounts of the Company and PDEX Franklin and all significant inter-company accounts and transactions have been eliminated. This subsidiary has no separate operations.

NET SALES

NET SALES	6 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
NET SALES	NOTE 3. NET SALES The following table presents the disaggregation of net sales by revenue recognition model (in thousands): Schedule of disaggregation of net sales Three Months Ended Six Months Ended 2024 2023 2024 2023 Net Sales: Over-time revenue recognition $ 41 $ 338 $ 89 $ 528 Point-in-time revenue recognition 16,752 12,250 31,597 23,998 Total net sales $ 16,793 $ 12,588 $ 31,686 $ 24,526 The timing of revenue recognition, billings, and cash collections results in billed accounts receivables, unbilled receivables (presented as deferred costs on our condensed consolidated balance sheets), and customer advances and deposits (presented as deferred revenue on our condensed consolidated balance sheets), where applicable. Amounts are generally billed as work progresses in accordance with agreed upon milestones. The over-time revenue recognition model consists of non-recurring engineering (“NRE”) and prototype services and typically relates to NRE services related to the evaluation, design, or customization of a medical device and is typically recognized over time utilizing an input measure of progress based on costs incurred compared to the estimated total costs upon completion. During the three and six months ended December 31, 2024 we recorded $ 0 14,000 no no The following tables summarize our contract assets (in thousands): Schedule of contract assets and liability As of and for the Three Months Ended As of and for the Six Months Ended 2024 2023 2024 2023 Contract assets beginning balance $ 211 $ 591 $ 262 $ 494 Expenses incurred during the year 40 $ 107 $ 97 $ 326 Amounts reclassified to cost of sales (99 ) (277 ) (201 ) (382 ) Amounts allocated to discounts for standalone selling price — (9 ) (6 ) (26 ) Contract assets ending balance $ 152 $ 412 $ 152 $ 412

COMPOSITION OF CERTAIN FINANCIA

COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS	6 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS	NOTE 4. COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS Inventory Inventory is stated at the lower of cost (first-in, first-out) or net realizable value and consists of the following (in thousands): Schedule of inventory December 31, June 30, Raw materials/purchased components $ 8,733 $ 6,703 Work in process 7,305 5,103 Sub-assemblies/finished components 2,883 2,342 Finished goods 690 1,121 Total inventory $ 19,611 $ 15,269 Investments Investments are stated at market value and consist of the following (in thousands): Schedule of investments December 31, 2024 June 30, Marketable equity securities: Short-term $ 4,671 $ 4,217 Long-term 1,619 1,563 Total Investments $ 6,290 $ 5,780 Investments at December 31, 2024 and June 30, 2024 had an aggregate cost basis $ 4.0 2.3 2.7 341,000 1.8 2.1 261,000 Of the total marketable equity securities at December 31, 2024 and June 30, 2024, $ 941,000 987,000 On October 6, 2023, in conjunction with the execution of a supply agreement with Monogram Technologies, Inc., formerly Monogram Orthopaedics Inc. (“Monogram”), we exercised a previously held warrant (the “Monogram Warrant”) in full in cash totaling $1,250,000 and received 1,828,551 shares of Monogram common stock (NasdaqCM: MGRM). The fair value of the Monogram common stock is reflected in short term in the table above. We invest surplus cash from time to time through our Investment Committee, which is comprised of one management director, Rick Van Kirk, and two non-management directors, Raymond Cabillot and Nicholas Swenson, who chairs the committee. Both Messrs. Cabillot and Swenson are active investors with extensive portfolio management expertise. We leverage the experience of these committee members to make investment decisions for the investment of our surplus operating capital or borrowed funds. Additionally, many of our securities holdings include stocks of public companies that either Messrs. Cabillot or Swenson or both may own from time to time either individually or through the investment funds that they manage, or other companies whose boards they sit on, such as Air T, Inc. Land and building Land and building consist of the following (in thousands): Schedule of land and building December 31, June 30, Land $ 3,684 $ 3,684 Building 2,815 2,815 Total 6,499 6,499 Less: accumulated depreciation (391 ) (344 ) $ 6,108 $ 6,155 In November 2020, we acquired the Franklin Property for a total purchase price of $ 6.5 30 Intangibles Intangibles consist of the following (in thousands): Schedule of intangibles December 31, June 30, Patent-related costs $ 208 $ 208 Less: accumulated amortization (168 ) (154 ) $ 40 $ 54 Patent-related costs consist of legal fees incurred in connection with both patent applications and a patent issuance and will be amortized over the estimated life of the product(s) that is or will be utilizing the technology, or expensed immediately in the event the patent office denies the issuance of the patent. Future amortization expense is expected to be $ 14,000 26,000

WARRANTY

WARRANTY	6 Months Ended
	Dec. 31, 2024
Guarantees and Product Warranties [Abstract]
WARRANTY	NOTE 5. WARRANTY Our warranty accrual is based on historical costs of warranty repairs and expected future identifiable warranty expenses and is included in accrued liabilities in the accompanying condensed consolidated balance sheets. As of December 31, 2024 and June 30, 2024, the warranty reserve amounted to $ 312,000 277,000 Information regarding the accrual for warranty costs for the three and six months ended December 31, 2024 and 2023, are as follows (in thousands): Schedule of accrual warranty costs As of and for the Three Months Ended As of and for the Six Months Ended 2024 2023 2024 2023 Beginning balance $ 300 $ 189 $ 277 $ 200 Accruals during the period 48 $ 29 $ 138 $ 53 Changes in estimates of prior period warranty accruals (7 ) 8 (25 ) 7 Warranty amortization (29 ) (32 ) (78 ) (66 ) Ending balance $ 312 $ 194 $ 312 $ 194

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE	6 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
NET INCOME (LOSS) PER SHARE	NOTE 6. NET INCOME (LOSS) PER SHARE We calculate basic net income (loss) per share by dividing net income by the weighted-average number of common shares outstanding during the reporting period. In income generating periods, the weighted-average number of common shares outstanding reflects the effects of potentially dilutive securities, which consist entirely of outstanding stock options, restricted stock, and performance awards. The following table presents reconciliations of the numerators and denominators of the basic and diluted earnings (loss) per share computations for net income (loss). Because we incurred a net loss for the six months ended December 31, 2023, basic and diluted loss were the same, as the inclusion of 64,800 common shares potentially issuable under the terms of outstanding performance awards would have had an anti-dilutive effect. In the tables below, net income amounts represent the numerator, and weighted average shares outstanding amounts represent the denominator (in thousands, except share and per share amounts): Schedule of net income per share Three Months Ended Six Months Ended 2024 2023 2024 2023 Basic: Net income (loss) $ 2,040 $ 500 $ 4,506 $ (115 ) Weighted average shares outstanding 3,261,145 3,546,901 3,314,207 3,546,819 Basic income (loss) per share $ 0.63 $ 0.14 $ 1.36 $ (0.03 ) Diluted: Net income (loss) $ 2,040 $ 500 $ 4,506 $ (115 ) Weighted average shares outstanding 3,261,145 3,546,901 3,314,207 3,546,819 Effect of dilutive securities 76,192 64,800 64,655 — Weighted average shares used in calculation of diluted earnings per share 3,337,337 3,611,701 3,378,862 3,546,819 Diluted income (loss) per share $ 0.61 $ 0.14 $ 1.33 $ (0.03 )

INCOME TAXES

INCOME TAXES	6 Months Ended
	Dec. 31, 2024
Cash paid during the period for income taxes by jurisdiction:
INCOME TAXES	NOTE 7. INCOME TAXES Deferred income taxes are provided on liability method whereby deferred tax assets and liabilities are recognized for temporary differences. Temporary differences are the differences between the reported amounts assets and liabilities and their tax basis. Deferred assets are reduced by valuation allowance when, in the opinion management, it is more likely than not that some portion or deferred tax assets will not realized. Deferred tax assets and liabilities are adjusted for the effects changes in tax laws and rates the date of enactment. Significant management judgment is required in determining our provision for income taxes and the recoverability our deferred tax assets. Such determination is based primarily on our historical taxable income, with some consideration given our estimates future taxable income by jurisdictions in which we operate and the period over which our deferred tax assets would be recoverable. We recognize accrued interest and penalties related to unrecognized tax benefits when applicable. As of December 31, 2024 and 2023, we recognized accrued interest of $ 54,000 61,000 21% 19% 60,000 24% 45% We are subject to U.S. federal income tax, as well as income tax of California and Colorado, as well as Massachusetts through fiscal year ended June 30, 2024. Our U.S. federal income taxes are currently open to audit under the statute of limitations by the Internal Revenue Service for the fiscal years ended June 30, 2021 and after. However, because of our prior net operating losses and research credit carryovers, our tax years from June 30, 2013 and after are open to audit. We do not anticipate significant change the total amount unrecognized tax benefits within the next months.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	6 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 8. SHARE-BASED COMPENSATION Our 2016 Equity Incentive Plan provides for the award of up to 1,500,000 200,000 372,000 18,000 Performance Awards In October 2023, the Compensation Committee of our Board (the “Compensation Committee”) reallocated previously forfeited performance awards for 15,200 10.17 7,000 30,000 14,000 45,000 41,000 1.50 On July 1, 2024, it was determined by the Compensation Committee that the vesting of performance awards for 40,000 25,134 273,000 Non-Qualified Stock Options In December 2020, the Compensation Committee granted non-qualified stock options for 310,000 The vesting of these stock options is tied to the completion of service periods that range from 18 months to 10.5 years from the date of grant and the achievement of our common stock trading at certain pre-determined prices. 16.72 104,000 168,000 208,000 335,000 1.4 Restricted Shares In November 2024, the Compensation Committee awarded 18,000 The shares vest ratably over five years from the date of grant. 857,000 19,000 838,000 Employee Stock Purchase Plan In September 2014, our Board approved the establishment of an Employee Stock Purchase Plan (the “ESPP”) and reserved 704,715 offering and purchase periods of six months, and bases the pricing to purchase shares of our common stock on a formula so as to result in a per-share purchase price that approximates a 15% discount from the market price of a share of our common stock at the end of the purchase period. During the three months ended December 31, 2024 and 2023, we did not record any share-based compensation expense relating to the ESPP, due to the fact that no 940 2,021 16.22 15.82 36,442 3,000 6,000

MAJOR CUSTOMERS AND SUPPLIERS

MAJOR CUSTOMERS AND SUPPLIERS	6 Months Ended
	Dec. 31, 2024
Risks and Uncertainties [Abstract]
MAJOR CUSTOMERS AND SUPPLIERS	NOTE 9. MAJOR CUSTOMERS AND SUPPLIERS Information with respect to customers accounted for sales in excess of 10% of our total sales either of three-month or the six-month periods ended December 31, 2024 and 2023, is as follows (in thousands, except percentages): Schedule of sales by major customers Three Months Ended December 31, 2024 2023 Amount Percent of Total Amount Percent of Total Net sales $ 16,793 100 % $ 12,588 100 % Customer concentration: Customer 1 $ 13,515 80 % $ 8,437 67 % Customer 2 1,784 11 % 1,494 12 % Customer 3 804 5 % 1,313 10 % Total $ 16,103 96 % $ 11,244 89 % Six Months Ended December 31, 2024 2023 Amount Percent of Total Amount Percent of Total Net sales $ 31,686 100 % $ 24,526 100 % Customer concentration: Customer 1 24,892 79 % 16,812 69 % Customer 2 3,621 11 % 2,703 11 % Customer 3 1,564 5 % 1,965 8 % Total $ 30,077 95 % $ 21,480 88 % Information with respect to accounts receivable from those customers that comprised more than 10% of our gross accounts receivable at either December 31, 2024 or June 30, 2024, is as follows (in thousands, except percentages): Schedule of accounts receivable December 31, 2024 June 30, 2024 Total gross accounts receivable $ 18,494 100 % $ 13,887 100 % Customer concentration: Customer 1 $ 15,582 84 % $ 10,488 76 % Customer 2 2,226 12 % 2,423 17 % Total. $ 17,808 96 % $ 12,911 93 % During the three months ended December 31, 2024 and 2023, we had three and four suppliers, respectively, that accounted for 10% 10% 1.8 657,000 485,000 1.4 372,000 416,000

NOTES PAYABLE AND FINANCING TRA

NOTES PAYABLE AND FINANCING TRANSACTIONS	6 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
NOTES PAYABLE AND FINANCING TRANSACTIONS	NOTE 10. NOTES PAYABLE AND FINANCING TRANSACTIONS Minnesota Bank & Trust As previously disclosed, we have several outstanding term loans as well as a revolving loan (the “Amended Revolving Loan”) under our Amended and Restated Credit Agreement with MBT (as subsequently amended, the “Amended Credit Agreement”). On 5.0 3.0 10,000 The balance on our outstanding loans (in thousands) is as follows (exclusive of unamortized loan fees): Schedule of unamortized loan December 31, 2024 June 30, 2024 Notes Payable: Term Loan A $ 3,320 $ 3,834 Term Loan B 494 571 Term Loan C 4,667 — Property Loan 4,450 4,551 Amended Revolving Loan 3,500 3,000 Total notes payable $ 16,431 $ 11,956 Term Loan A and B both bear interest at a fixed rate of 3.84% 3.55% 5% 2.5% The Amended Revolving Loan bears interest at an annual rate equal to the greater of (a) 4%, or (b) t November 1, 2027 August 1, 2029 November 1, 2030 3.1 December 29, 2026 Any payment on Term Loan A, Term Loan B, Term Loan C, the Property Loan, or Amended Revolving Loan (collectively, the “Loans”) not made within seven days after the due date is subject to a late payment fee equal to 5% 3% The Amended Credit Agreement, Amended Security Agreement, Property Loan Security Agreements,Term Note A, Term Note B, Term Note C, Property Note, and Amended Revolving Note contain representations and warranties, affirmative, negative and financial covenants, and events of default that are customary for loans of this type. We believe that we are in compliance with all of our debt covenants as of December 31, 2024, but there can be no assurance that we will remain in compliance for the duration of the term of the Loans.

COMMON STOCK

COMMON STOCK	6 Months Ended
	Dec. 31, 2024
Equity [Abstract]
COMMON STOCK	NOTE 11. COMMON STOCK Share Repurchase Program In December 2019, our Board approved a new share repurchase program authorizing us to repurchase up to one million shares of our common stock, as the prior repurchase plan authorized by our Board in 2013 was nearing completion. In accordance with, and as part of, these share repurchase programs, our Board approved the adoption of several prearranged share repurchase plans intended to qualify for the safe harbor provided by Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (“10b5-1 Plan” or “Plan”). During the three and six months ended December 31, 2024, we repurchased 38,172 130,148 1.2 3.5 6,285 107,000 1,511,497 24.2

LEASES

LEASES	6 Months Ended
	Dec. 31, 2024
Leases
LEASES	NOTE 12. LEASES Our operating lease right-of-use asset and long-term liability are presented separately on our condensed consolidated balance sheets. The current portion of our operating lease liability as of December 31, 2024, in the amount of $ 476,000 As of December 31, 2024, our operating lease has a remaining lease term of two years and nine months and an imputed interest rate of 5.53% 135,000 265,000 131,000 258,000 As of December 31, 2024, the maturity of our lease liability is as follows (in thousands): Schedule of maturities of lease liabilities Operating Lease Fiscal Year: 2025 269 2026 551 2027 567 2028 143 Total lease payments 1,530 Less imputed interest: (115 ) Total $ 1,415

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13. COMMITMENTS AND CONTINGENCIES Legal Matters We may be involved from time to time in various legal proceedings arising either in the ordinary course of our business or incidental to our business. There can be no certainty, however, that we may not ultimately incur liability or that such liability will not be material and adverse.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Dec. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14. SUBSEQUENT EVENTS We have evaluated subsequent events through the date of this report. There were no subsequent events that require disclosure.

NET SALES (Tables)

NET SALES (Tables)	6 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of net sales	Schedule of disaggregation of net sales Three Months Ended Six Months Ended 2024 2023 2024 2023 Net Sales: Over-time revenue recognition $ 41 $ 338 $ 89 $ 528 Point-in-time revenue recognition 16,752 12,250 31,597 23,998 Total net sales $ 16,793 $ 12,588 $ 31,686 $ 24,526
Schedule of contract assets and liability	Schedule of contract assets and liability As of and for the Three Months Ended As of and for the Six Months Ended 2024 2023 2024 2023 Contract assets beginning balance $ 211 $ 591 $ 262 $ 494 Expenses incurred during the year 40 $ 107 $ 97 $ 326 Amounts reclassified to cost of sales (99 ) (277 ) (201 ) (382 ) Amounts allocated to discounts for standalone selling price — (9 ) (6 ) (26 ) Contract assets ending balance $ 152 $ 412 $ 152 $ 412

COMPOSITION OF CERTAIN FINANC_2

COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS (Tables)	6 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of inventory	Schedule of inventory December 31, June 30, Raw materials/purchased components $ 8,733 $ 6,703 Work in process 7,305 5,103 Sub-assemblies/finished components 2,883 2,342 Finished goods 690 1,121 Total inventory $ 19,611 $ 15,269
Schedule of investments	Schedule of investments December 31, 2024 June 30, Marketable equity securities: Short-term $ 4,671 $ 4,217 Long-term 1,619 1,563 Total Investments $ 6,290 $ 5,780
Schedule of land and building	Schedule of land and building December 31, June 30, Land $ 3,684 $ 3,684 Building 2,815 2,815 Total 6,499 6,499 Less: accumulated depreciation (391 ) (344 ) $ 6,108 $ 6,155
Schedule of intangibles	Schedule of intangibles December 31, June 30, Patent-related costs $ 208 $ 208 Less: accumulated amortization (168 ) (154 ) $ 40 $ 54

WARRANTY (Tables)

WARRANTY (Tables)	6 Months Ended
	Dec. 31, 2024
Guarantees and Product Warranties [Abstract]
Schedule of accrual warranty costs	Schedule of accrual warranty costs As of and for the Three Months Ended As of and for the Six Months Ended 2024 2023 2024 2023 Beginning balance $ 300 $ 189 $ 277 $ 200 Accruals during the period 48 $ 29 $ 138 $ 53 Changes in estimates of prior period warranty accruals (7 ) 8 (25 ) 7 Warranty amortization (29 ) (32 ) (78 ) (66 ) Ending balance $ 312 $ 194 $ 312 $ 194

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)	6 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of net income per share	Schedule of net income per share Three Months Ended Six Months Ended 2024 2023 2024 2023 Basic: Net income (loss) $ 2,040 $ 500 $ 4,506 $ (115 ) Weighted average shares outstanding 3,261,145 3,546,901 3,314,207 3,546,819 Basic income (loss) per share $ 0.63 $ 0.14 $ 1.36 $ (0.03 ) Diluted: Net income (loss) $ 2,040 $ 500 $ 4,506 $ (115 ) Weighted average shares outstanding 3,261,145 3,546,901 3,314,207 3,546,819 Effect of dilutive securities 76,192 64,800 64,655 — Weighted average shares used in calculation of diluted earnings per share 3,337,337 3,611,701 3,378,862 3,546,819 Diluted income (loss) per share $ 0.61 $ 0.14 $ 1.33 $ (0.03 )

MAJOR CUSTOMERS AND SUPPLIERS (

MAJOR CUSTOMERS AND SUPPLIERS (Tables)	6 Months Ended
	Dec. 31, 2024
Risks and Uncertainties [Abstract]
Schedule of sales by major customers	Schedule of sales by major customers Three Months Ended December 31, 2024 2023 Amount Percent of Total Amount Percent of Total Net sales $ 16,793 100 % $ 12,588 100 % Customer concentration: Customer 1 $ 13,515 80 % $ 8,437 67 % Customer 2 1,784 11 % 1,494 12 % Customer 3 804 5 % 1,313 10 % Total $ 16,103 96 % $ 11,244 89 % Six Months Ended December 31, 2024 2023 Amount Percent of Total Amount Percent of Total Net sales $ 31,686 100 % $ 24,526 100 % Customer concentration: Customer 1 24,892 79 % 16,812 69 % Customer 2 3,621 11 % 2,703 11 % Customer 3 1,564 5 % 1,965 8 % Total $ 30,077 95 % $ 21,480 88 %
Schedule of accounts receivable	Schedule of accounts receivable December 31, 2024 June 30, 2024 Total gross accounts receivable $ 18,494 100 % $ 13,887 100 % Customer concentration: Customer 1 $ 15,582 84 % $ 10,488 76 % Customer 2 2,226 12 % 2,423 17 % Total. $ 17,808 96 % $ 12,911 93 %

NOTES PAYABLE AND FINANCING T_2

NOTES PAYABLE AND FINANCING TRANSACTIONS (Tables)	6 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of unamortized loan	Schedule of unamortized loan December 31, 2024 June 30, 2024 Notes Payable: Term Loan A $ 3,320 $ 3,834 Term Loan B 494 571 Term Loan C 4,667 — Property Loan 4,450 4,551 Amended Revolving Loan 3,500 3,000 Total notes payable $ 16,431 $ 11,956

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Dec. 31, 2024
Leases
Schedule of maturities of lease liabilities	Schedule of maturities of lease liabilities Operating Lease Fiscal Year: 2025 269 2026 551 2027 567 2028 143 Total lease payments 1,530 Less imputed interest: (115 ) Total $ 1,415

NET SALES (Details)

NET SALES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Net Sales:
Over-time revenue recognition	$ 41	$ 338	$ 89	$ 528
Point-in-time revenue recognition	16,752	12,250	31,597	23,998
Total net sales	$ 16,793	$ 12,588	$ 31,686	$ 24,526

NET SALES (Details 1)

NET SALES (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Contract assets beginning balance	$ 211	$ 591	$ 262	$ 494
Expenses incurred during the year	40	107	97	326
Amounts reclassified to cost of sales	(99)	(277)	(201)	(382)
Amounts allocated to discounts for standalone selling price		(9)	(6)	(26)
Contract assets ending balance	$ 152	$ 412	$ 152	$ 412

NET SALES (Details Narrative)

NET SALES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue recognized	$ 0	$ 0	$ 14,000	$ 0
Deferred revenue	$ 0	$ 0	$ 0	$ 0

COMPOSITION OF CERTAIN FINANC_3

COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials/purchased components	$ 8,733	$ 6,703
Work in process	7,305	5,103
Sub-assemblies/finished components	2,883	2,342
Finished goods	690	1,121
Total inventory	$ 19,611	$ 15,269

COMPOSITION OF CERTAIN FINANC_4

COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS (Details 1) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Short-term	$ 4,671	$ 4,217
Long-term	1,619	1,563
Total Investments	$ 6,290	$ 5,780

COMPOSITION OF CERTAIN FINANC_5

COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS (Details 2) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Property, Plant and Equipment [Line Items]
Total	$ 6,499	$ 6,499
Less: accumulated depreciation	(391)	(344)
Land and building	6,108	6,155
Land [Member]
Property, Plant and Equipment [Line Items]
Total	3,684	3,684
Building [Member]
Property, Plant and Equipment [Line Items]
Total	$ 2,815	$ 2,815

COMPOSITION OF CERTAIN FINANC_6

COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS (Details 3) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Patent-related costs	$ 208	$ 208
Less accumulated amortization	(168)	(154)
Intangible assets, net	$ 40	$ 54

COMPOSITION OF CERTAIN FINANC_7

COMPOSITION OF CERTAIN FINANCIAL STATEMENT ITEMS (Details Narrative) - USD ($)		6 Months Ended	12 Months Ended
	Oct. 06, 2024	Dec. 31, 2024	Jun. 30, 2024	Nov. 30, 2020
Property, Plant and Equipment [Line Items]
Available for sale securities aggregate cost		$ 4,000,000	$ 4,000,000
Investments included net unrealized gains (losses)		2,300,000	1,800,000
Gross unrealized gains		2,700,000	2,100,000
Gross unrealized losses		341,000	261,000
Marketable equity securities		$ 941,000	$ 987,000
Warrant description	On October 6, 2023, in conjunction with the execution of a supply agreement with Monogram Technologies, Inc., formerly Monogram Orthopaedics Inc. (“Monogram”), we exercised a previously held warrant (the “Monogram Warrant”) in full in cash totaling $1,250,000 and received 1,828,551 shares of Monogram common stock (NasdaqCM: MGRM). The fair value of the Monogram common stock is reflected in short term in the table above.
Amortization period		30 years
Future amortization expense, fiscal 2025		$ 14,000
Future amortization expense, fiscal 2026		$ 26,000
Franklin Property [Member]
Property, Plant and Equipment [Line Items]
Purchase price				$ 6,500,000

WARRANTY (Details)

WARRANTY (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Guarantees and Product Warranties [Abstract]
Beginning balance	$ 300	$ 189	$ 277	$ 200
Accruals during the period	48	29	138	53
Changes in estimates of prior period warranty accruals	(7)	8	(25)	7
Warranty amortization	(29)	(32)	(78)	(66)
Ending balance	$ 312	$ 194	$ 312	$ 194

WARRANTY (Details Narrative)

WARRANTY (Details Narrative) - USD ($)	Dec. 31, 2024	Jun. 30, 2024
Guarantees and Product Warranties [Abstract]
Warranty reserve	$ 312,000	$ 277,000

NET INCOME (LOSS) PER SHARE (De

NET INCOME (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Basic:
Net income (loss)	$ 2,040	$ 500	$ 4,506	$ (115)
Weighted average shares outstanding	3,261,145	3,546,901	3,314,207	3,546,819
Basic income (loss) per share	$ 0.63	$ 0.14	$ 1.36	$ (0.03)
Diluted:
Net income (loss)	$ 2,040	$ 500	$ 4,506	$ (115)
Weighted average shares outstanding	3,261,145	3,546,901	3,314,207	3,546,819
Effect of dilutive securities	76,192	64,800	64,655
Weighted average shares used in calculation of diluted earnings per share	3,337,337	3,611,701	3,378,862	3,546,819
Diluted income (loss) per share	$ 0.61	$ 0.14	$ 1.33	$ (0.03)

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Cash paid during the period for income taxes by jurisdiction:
Accrued interest related to unrecognized tax benefits	$ 54,000	$ 61,000	$ 54,000	$ 61,000
Effective tax rate	21%	19%	24%	45%
Unrealized losses on investments					$ 60,000

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details Narrative) - USD ($)		1 Months Ended				3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 02, 2024	Nov. 30, 2024	Oct. 31, 2023	Dec. 31, 2020	Sep. 30, 2014	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2021	Dec. 31, 2016
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards granted during period	40,000
Share-based compensation expense performance awards						$ 7,000	$ 30,000	$ 14,000	$ 45,000
Unrecognized compensation cost						41,000		$ 41,000
Weighted-average remaining contractual life								1 year 6 months
Number of shares issued	25,134
Payroll tax liabilities	$ 273,000
Non Qualified Stock Options [Member] | Directors And Certain Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average fair value										$ 16.72
Previously Forfeited Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards granted during period			15,200
Weighted average fair value			$ 10.17
Equity Incentive Plan 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available to be awarded											1,500,000
Equity Incentive Plan 2016 [Member] | Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards granted during period								200,000
Equity Incentive Plan 2016 [Member] | Non Qualified Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards granted during period								372,000
Equity Incentive Plan 2016 [Member] | Non Qualified Stock Options [Member] | Directors And Certain Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards granted during period				310,000
Share-based compensation expense performance awards						104,000	168,000	$ 208,000	335,000
Unrecognized compensation cost						1,400,000		$ 1,400,000
Period for award description				The vesting of these stock options is tied to the completion of service periods that range from 18 months to 10.5 years from the date of grant and the achievement of our common stock trading at certain pre-determined prices.
Equity Incentive Plan 2016 [Member] | Restricted Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards granted during period								18,000
Equity Incentive Plan 2016 [Member] | Restricted Shares [Member] | Directors And Certain Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of awards granted during period		18,000
Share-based compensation expense performance awards								$ 19,000
Unrecognized compensation cost						838,000		838,000
Period for award description		The shares vest ratably over five years from the date of grant.
Fair value of restricted shares		$ 857,000
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation expense performance awards						$ 0	$ 0	$ 3,000	$ 6,000
Number of shares reserved for future issuance					704,715
Description of employee stock purchase plan					offering and purchase periods of six months, and bases the pricing to purchase shares of our common stock on a formula so as to result in a per-share purchase price that approximates a 15% discount from the market price of a share of our common stock at the end of the purchase period.
Number of shares purchased and allocated to employee								940	2,021
Exercise price								$ 16.22	$ 15.82
Number of shares purchased total								36,442

MAJOR CUSTOMERS & SUPPLIERS (De

MAJOR CUSTOMERS & SUPPLIERS (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Concentration Risk [Line Items]
Net sales	$ 16,793	$ 12,588	$ 31,686	$ 24,526
Sales [Member] | Customer Concentration Risk [Member] | Customer [Member]
Concentration Risk [Line Items]
Net sales	$ 16,793	$ 12,588	$ 31,686	$ 24,526
Percentage of concentrations risk	100%	100%	100%	100%
Sales [Member] | Customer Concentration Risk [Member] | Customer 1 [Member]
Concentration Risk [Line Items]
Net sales	$ 13,515	$ 8,437	$ 24,892	$ 16,812
Percentage of concentrations risk	80%	67%	79%	69%
Sales [Member] | Customer Concentration Risk [Member] | Customer 2 [Member]
Concentration Risk [Line Items]
Net sales	$ 1,784	$ 1,494	$ 3,621	$ 2,703
Percentage of concentrations risk	11%	12%	11%	11%
Sales [Member] | Customer Concentration Risk [Member] | Customer 3 [Member]
Concentration Risk [Line Items]
Net sales	$ 804	$ 1,313	$ 1,564	$ 1,965
Percentage of concentrations risk	5%	10%	5%	8%
Sales [Member] | Customer Concentration Risk [Member] | Total Customer [Member]
Concentration Risk [Line Items]
Net sales	$ 16,103	$ 11,244	$ 30,077	$ 21,480
Percentage of concentrations risk	96%	89%	95%	88%

MAJOR CUSTOMERS & SUPPLIERS (_2

MAJOR CUSTOMERS & SUPPLIERS (Details 1) - Accounts Receivable [Member] - Customer Concentration Risk [Member] - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2024	Jun. 30, 2024
Customer [Member]
Concentration Risk [Line Items]
Total gross accounts receivable	$ 18,494	$ 13,887
Percentage of concentrations risk	100%	100%
Customer 1 [Member]
Concentration Risk [Line Items]
Total gross accounts receivable	$ 15,582	$ 10,488
Percentage of concentrations risk	84%	76%
Customer 2 [Member]
Concentration Risk [Line Items]
Total gross accounts receivable	$ 2,226	$ 2,423
Percentage of concentrations risk	12%	17%
Total Customer [Member]
Concentration Risk [Line Items]
Total gross accounts receivable	$ 17,808	$ 12,911
Percentage of concentrations risk	96%	93%

MAJOR CUSTOMERS AND SUPPLIERS_2

MAJOR CUSTOMERS AND SUPPLIERS (Details Narrative) - Accounts Payable [Member] - Supplier Concentration Risk [Member] - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Three Suppliers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	10%		10%	10%
Four Suppliers [Member]
Concentration Risk [Line Items]
Concentration risk percentage		10%
Suppliers 1 [Member]
Concentration Risk [Line Items]
Amounts owed	$ 1,800,000		$ 1,800,000		$ 1,400,000
Suppliers 2 [Member]
Concentration Risk [Line Items]
Amounts owed	657,000		657,000		372,000
Suppliers 3 [Member]
Concentration Risk [Line Items]
Amounts owed	$ 485,000		$ 485,000		$ 416,000

NOTES PAYABLE AND FINANCING T_3

NOTES PAYABLE AND FINANCING TRANSACTIONS (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Jun. 30, 2024
Short-Term Debt [Line Items]
Total notes payable	$ 16,431	$ 11,956
Term Loan A [Member]
Short-Term Debt [Line Items]
Total notes payable	3,320	3,834
Term Loan B [Member]
Short-Term Debt [Line Items]
Total notes payable	494	571
Term Loan C [Member]
Short-Term Debt [Line Items]
Total notes payable	4,667
Property Loan [Member]
Short-Term Debt [Line Items]
Total notes payable	4,450	4,551
Amended Revolving Loan [Member]
Short-Term Debt [Line Items]
Total notes payable	$ 3,500	$ 3,000

NOTES PAYABLE AND FINANCING T_4

NOTES PAYABLE AND FINANCING TRANSACTIONS (Details Narrative) - Minnesota Bank And Trust [Member] - USD ($)	6 Months Ended
	Dec. 31, 2024	Jul. 31, 2024
Debt Instrument [Line Items]
Percentage of late payment fee	5%
Increased percentage of default late payment	3%
Term Loan A and B [Member]
Debt Instrument [Line Items]
Interest rate	3.84%
Maturity date	Nov. 01, 2027
Property Loan [Member]
Debt Instrument [Line Items]
Interest rate	3.55%
Maturity date	Nov. 01, 2030
Balloon payment	$ 3,100,000
Term Loan C [Member]
Debt Instrument [Line Items]
Interest rate	5%
Maturity date	Aug. 01, 2029
Amended Revolving Loan [Member]
Debt Instrument [Line Items]
Interest rate	2.50%
Maturity date	Dec. 29, 2026
Term Loan C [Member]
Debt Instrument [Line Items]
Loan amount		$ 5,000,000
Loan repaid amount		3,000,000
Loan origination fee		$ 10,000

COMMON STOCK (Details Narrative

COMMON STOCK (Details Narrative) - Tenb 51 Plan [Member] - Share Repurchase Program [Member] - USD ($)		3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Share Repurchase Program [Line Items]
Number of shares repurchased, shares		38,172	6,285	130,148	6,285
Number of shares repurchased, value		$ 1,200,000	$ 107,000	$ 3,500,000	$ 107,000
Cumulative Basis [Member]
Share Repurchase Program [Line Items]
Number of shares repurchased, shares	1,511,497
Number of shares repurchased, value	$ 24,200,000

LEASES (Details)

LEASES (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Leases
2025	$ 269
2026	551
2027	567
2028	143
Total lease payments	1,530
Less imputed interest	(115)
Total	$ 1,415

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Leases
Operating lease liability current portion	$ 476,000		$ 476,000
Imputed interest rate, percentage	5.53%		5.53%
Cash paid for amounts included in the lease liability	$ 135,000	$ 131,000	$ 265,000	$ 258,000